AIxCrypto Holdings (AIXC) risk factors, FY2024 10-K

Risks Related to Our Business

1. 01Various factors raise substantial doubt about the Company’s ability to continue as a going concern
2. 02Any failure to develop or maintain effective internal controls over financial reporting or difficulties encountered in implementing or improving our internal controls over financial reporting could harm our operating results and prevent us from meeting our reporting obligations
3. 03Continued uncertain economic conditions, including inflation and the risk of a global recession could impair our ability to forecast and may harm our business, operating results, including our revenue growth and profitability, financial condition and cash flows
4. 04Our business and operations would suffer in the event of computer system failures, cyberattacks or a deficiency in our cybersecurity or a natural disaster
5. 05Our future growth may be limited
6. 06We will need additional financing in order to grow our business
7. 07Geopolitical conditions, including direct or indirect acts of war or terrorism, could have an adverse effect on our operations and financial results
8. 08We are subject to litigation, which could result in significant expenses and negatively impact our business, financial condition, and results of operations

Risks related to regulatory approval

1. 09Changes in product candidate manufacturing or formulation may result in additional costs or delay
2. 10Even if our product candidates receive regulatory approval, we will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense and limit how we manufacture and market our products
3. 11If we are slow or unable to adapt to changes in existing requirements, standards of care, or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and be subject to regulatory enforcement action

Risks related to commercialization

1. 12If we are unable to establish effective marketing, sales and distribution capabilities or enter into agreements with third parties to market and sell our product candidates, if they are approved, the revenues that we generate may be limited and we may never become profitable
2. 13As we continue to evolve from a company primarily involved in research and development to a company also expected to be involved in commercialization, we may encounter difficulties in managing our growth and expanding our operations successfully
3. 14Our product candidates are based on a novel approach to the treatment of cancer, which makes it difficult to predict the time and cost of product candidate development
4. 15If our product candidates do not achieve broad market acceptance, the revenues that we generate from their sales may be limited, and we may never become profitable
5. 16The successful commercialization of our product candidates, if approved, will depend in part on the extent to which government authorities and health insurers establish adequate reimbursement levels and pricing policies
6. 17The size of the potential market for our product candidates is difficult to estimate and, if any of our assumptions are inaccurate, the actual markets for our product candidates may be smaller than our estimates

Risks Related to the Ownership of Our Securities

1. 18We have a large number of authorized but unissued shares of our common stock which will dilute existing ownership positions when issued
2. 19Our common stock may be affected by limited trading volume and price fluctuations, which could adversely impact the value of our common stock
3. 20We may need, but be unable, to obtain additional funding on satisfactory terms, which could dilute our stockholders or impose burdensome financial restrictions on our business